NRG Oncology’s GOG-0218 Trial Leads to FDA Approval of Chemotherapy with Bevacizumab for Women with Ovarian Cancer Following Initial Surgery

Thank you to our patients who participated in this clinical trial!

PHILADELPHIA, PA —The U.S. Food and Drug Administration (FDA) recently approved the use of bevacizumab (Avastin®) in combination with carboplatin and paclitaxel followed by Avastin as a single agent, as a treatment for women with advanced stage III or IV ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection. The FDA approval stems from the results of the double blind, placebo-controlled, phase 3 NRG Oncology trial GOG-0218, which revealed the addition of bevacizumab improved progression-free survival (PFS) for women when compared to chemotherapy alone. GOG-0218 was conducted by the Gynecologic Oncology Group (GOG, now part of NRG Oncology) and sponsored by the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) under its Cooperative Research and Development Agreement with Genentech, a member of the Roche Group, for bevacizumab.

Read the full press release here.